Peptide education
GHRP-2
GHRP-2, known in medicine as pralmorelin, is a synthetic hexapeptide that triggers growth hormone release through the ghrelin receptor pathway. It holds a distinction none of its gray-market cousins can claim: an actual regulatory approval, as Japan's GHRP Kaken 100 injection for testing growth hormone secretion. It also carries two findings its marketing prefers to skip: in a controlled human study it made people eat more, not less, and it moves ACTH and prolactin alongside GH. The muscle, fat-loss, and recovery uses sold under the name have no controlled healthy-adult outcome data behind them.
GHRP-2 is the rare secretagogue with a real approval, a Japanese diagnostic test, and human data that cuts against its own marketing: it increased food intake in a controlled study, and it is not GH-selective. Diagnostic use and acute hormone effects are documented; the physique promises are not.
Overview
Quick answer
A Japanese diagnostic pralmorelin injection, a controlled human infusion study, a clinic peptide program, a Reddit report, and a gray-market vial are not the same thing. The same molecule name appears across all of them, but the product controls, route, dose, frequency, oversight, and evidence differ.
What is GHRP-2?
GHRP-2 is pralmorelin, a synthetic hexapeptide ghrelin-receptor agonist that stimulates GH release. It is not recombinant GH and not a GHRH analog like sermorelin or tesamorelin: it works the ghrelin-receptor side of the GH axis.
What is it actually used for?
Its one approved job is diagnostic: in Japan, a single fasting IV injection is used to test whether the pituitary can secrete GH. Everything else, GH optimization, bulking, cutting, recovery, sleep, anti-aging, is off-label market use without outcome trials.
What study and label schedules are reported?
The Japanese label is the concrete one: 100 mcg IV after fasting for adults, 2 mcg/kg capped at 100 mcg for children, with GH sampled over the following hour. Beyond that, human research used subcutaneous infusions, pediatric dosing blocks, intranasal programs, and critical-illness protocols: study settings, not public schedules.
What do clinics, forums, vendors, and gray-market sellers discuss?
Clinics and vendors file it under recovery, fat loss, lean mass, and vitality, usually next to purity percentages and COAs. Forums talk about blends, hunger, side effects, and cloudy or unstable-looking solutions: the unfiltered version of the product-quality question.
What can the evidence actually support?
GH provocation, diagnostic discrimination, and an acute appetite increase, that last one measured as about 36% more food eaten during infusion in a small crossover study. The step from those findings to better body composition, strength, or recovery in healthy adults is where the evidence runs out.
Reported practice
Commonly reported protocol
Community secretagogue protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
The Japanese label and adult diagnostic studies support GHRP-2 as a GH stimulation test. That is a diagnostic claim, not a lifestyle or physique claim.
A controlled study in healthy lean men reported higher food intake during GHRP-2 exposure, and obesity research found preserved appetite response. That matters because it complicates simple fat-loss marketing.
Human physiology studies reported ACTH and prolactin responses alongside GH effects. GHRP-2 is not limited to one hormone axis.
Healthy-adult lean-mass, strength, recovery, and fat-loss claims mostly come from extrapolation, clinics, vendors, and online discussion rather than direct outcome studies.
FDA materials raise concerns around peptide impurities, aggregation, immunogenicity, and characterization complexity. A vendor purity percentage or basic COA leaves those batch-specific risks open.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| GHRP-2 raises growth hormone. | This statement is well supported. Controlled human studies and the Japanese diagnostic protocol show that GHRP-2 can provoke GH release. | GHRP-2 binds the growth hormone secretagogue receptor and works through a ghrelin-like pathway. Human mutation and combination studies suggest partial action beyond a simple GHRH pathway. | Clinic and vendor pages often start with the GH response and turn it into broader wellness or physique claims. | Supported for acute GH provocation. Muscle, fat-loss, recovery, and anti-aging claims are separate outcome claims. |
| GHRP-2 is an accepted diagnostic test for growth hormone deficiency. | Japan markets pralmorelin injection for GH secretion deficiency testing. Adult validation work reported a peak GH cutoff around 15 mcg/L aligned with severe deficiency classification, and a Japanese comparison study evaluated it against insulin tolerance and arginine tests. | Diagnostic use depends on provoking the pituitary growth-hormone axis and measuring the response, not on treating the underlying cause. | Online peptide discussions rarely stay within this diagnostic use; they usually shift quickly to higher-GH or body-composition goals. | Supported as diagnostic use, especially in Japan. It is not the same as approval for repeated wellness or performance use. |
| GHRP-2 increases appetite. | In a randomized crossover study of seven healthy lean men, a 1 mcg/kg/hour subcutaneous infusion for 270 minutes increased food intake during a meal compared with saline. Later obesity work also reported retained appetite response. | The ghrelin-like receptor pathway helps explain why appetite can move alongside GH. | Users and clinics often mention hunger, bulking, or appetite effects, though reports vary by person, route, dose, and blend. | Supported as an acute human effect. Extra intake is not the same as healthy weight gain, and it cuts against simple fat-loss marketing. |
| GHRP-2 builds muscle, improves recovery, or improves performance. | The human studies mostly measured hormones, diagnostic response, appetite, growth-related pediatric outcomes, older-adult biomarkers, or disease-state endocrine physiology. They did not measure controlled strength, recovery, or performance benefits in healthy adults. | Raising GH and IGF-related markers gives marketers a plausible rationale, but physiology does not equal measured functional benefit. | Clinics, vendors, forums, and gray-market listings often discuss GHRP-2 for lean mass, recovery, sleep, and anti-aging, sometimes in blends with CJC-1295 or ipamorelin. | Common in marketing and user reports, but not backed here by a controlled healthy-adult outcome study. |
| GHRP-2 burns fat. | No strong controlled human fat-loss outcome is available. The acute appetite data point in the opposite direction for many people. | GH-axis changes can influence substrate use, but reliable fat-loss evidence in healthy adults is missing here. | Fat-loss and cutting language appears on clinic and vendor pages and in gray-market discussion, often without controlled outcome data. | Fat-loss language is common in marketing, but the cited clinical literature is mainly endocrine and diagnostic context. |
| GHRP-2 is selective for growth hormone only. | Healthy-men and hypothalamic-pituitary disorder studies reported ACTH and prolactin responses, with fasting increasing several hormone peaks. | Ghrelin-pathway signaling interacts with more than one endocrine axis, and critical-illness studies reported broader pituitary hormone effects. | "Clean GH release" language appears in secretagogue marketing, but it misses the multi-axis findings in human physiology studies. | Misleading. GHRP-2 is better described as a GH secretagogue with documented endocrine spillover. |
| Can seller paperwork show a gray-market GHRP-2 vial matches studied material? | A seller purity claim is only lot paperwork. Matching an unapproved injectable vial to a studied or labeled product requires identity, concentration, sterility, impurity, and route-specific evidence. | FDA's risk discussion focuses on peptide-related impurities, aggregation, immunogenicity, and characterization challenges, not just one purity number. | Vendor pages commonly advertise 99% purity, third-party testing, or COA access, while forums describe cloudy solutions, blend uncertainty, and handling concerns. | A COA can be one narrow data point. Reliability still depends on sterile injectable quality, correct concentration, impurity control, and whether the vial is suitable for the claimed route. |
Bottom line
Main takeaway
GHRP-2 is a GH secretagogue with a genuine diagnostic approval in Japan and real human hormone and appetite data. The bodybuilding and fat-loss reputation is not backed anywhere near as well, and its own appetite finding argues against the cutting pitch.
Keep it separate from GH, GHRH analogs, tesamorelin, and ipamorelin: it has its own receptor, its own appetite effect, and its own ACTH and prolactin spillover. Those last two traits are exactly what secretagogue marketing tends to omit.
Weight the Japanese product information, the adult diagnostic validation and comparison studies, the Laferrère appetite work, the endocrine-spillover physiology, and FDA's compounding materials above any clinic or vendor claim.
Identity
What it is
GHRP-2 is a synthetic hexapeptide ghrelin-receptor agonist, known formally as pralmorelin. Japan's product information describes GH release driven mainly through hypothalamic mediation, and human studies confirm the response is real and strong.
It occupies a strange position in this market: the molecule with the best paperwork. Pralmorelin hydrochloride is an approved diagnostic injection in Japan, with adult validation work establishing a peak-GH cutoff around 15 mcg/L against insulin-tolerance-test classification and a comparison study showing strong performance for severe adult GH deficiency. None of that approval touches repeated wellness or physique use.
Its own data then complicates the marketing in two directions. In a randomized crossover study, healthy lean men ate about 36% more during a GHRP-2 infusion than on saline, and obesity research found the appetite response preserved: awkward facts for a compound sold next to cutting stacks. Physiology studies also recorded ACTH and prolactin rises, higher after fasting, which ends any clean-GH-only description.
What remains is extrapolation. Older-adult infusions raised GH and IGF-related biomarkers without showing strength or lean-mass benefit, a six-child exploratory study is too small to generalize, and critical-illness endocrine work belongs to that setting. The healthy-adult muscle, recovery, and fat-loss claims live in clinic and vendor copy, not in the study record.
How people talk about it online
Clinic and vendor pages slot GHRP-2 into recovery, fat-loss, lean-mass, and anti-aging categories, often advertising research-use vials with 99% purity and COA badges. Notice what that copy never mentions: the human appetite finding and the ACTH and prolactin data that come with the molecule.
Forum threads supply the ground truth: CJC-1295 or ipamorelin blends, hunger reports, side effects, and recurring posts about cloudy or unstable-looking solutions. Those are not efficacy data, but they are a live demonstration that vial contents and handling are open questions in this market.
One peer-reviewed case report deserves attention on its own: GHRP-2 was identified in tablets sold as a nutritional supplement. Hidden exposure outside obvious peptide-vial channels is a documented event, not a theoretical risk.
Use context
Routes, doses, and cycle patterns
GHRP-2 use details vary sharply by setting. Labeled and study protocols include fasting IV diagnostic boluses, subcutaneous infusions, pediatric dose-escalation schedules, intranasal programs, and critical-illness endocrine infusions. Clinic and gray-market discussion often talks about subcutaneous vials and blends, but exact amount, frequency, and cycle reporting is inconsistent.
Human studies and product labels
Japan adult diagnostic test
- Purpose
- Diagnosis of growth hormone secretion deficiency
- Context
- Japanese product label
- Route
- IV
- Amount
- 100 mcg
- Frequency
- Single fasting diagnostic administration
- Duration
- GH sampled before injection and at 15, 30, 45, and 60 minutes
The Japanese label gives the clearest protocol: a diagnostic stimulation test, not a repeated wellness or physique regimen.
Japan pediatric diagnostic test
- Purpose
- Diagnosis of growth hormone secretion deficiency in ages 4 to under 18
- Context
- Japanese product label
- Route
- IV
- Amount
- 2 mcg/kg, capped at 100 mcg above 50 kg body weight
- Frequency
- Single fasting diagnostic administration
- Duration
- Short diagnostic sampling period
The label gives a weight-based pediatric diagnostic amount and also notes that the label does not provide trial support for children under 4 years, neonates, infants, or low-birthweight infants.
Adult diagnostic validation study
- Purpose
- Severe adult growth hormone deficiency classification
- Context
- Primary human diagnostic study
- Route
- IV
- Amount
- 100 mcg
- Frequency
- Single dose after overnight fast
- Duration
- GH measured over 2 hours
The study reported GH peaks within 60 minutes and used a peak GH cutoff around 15 mcg/L against insulin tolerance test classification.
Healthy-men appetite study
- Purpose
- Acute food intake and GH response
- Context
- Randomized crossover human study
- Route
- Subcutaneous infusion
- Amount
- 1 mcg/kg/hour
- Frequency
- Continuous infusion during the test period
- Duration
- 270 minutes before an ad libitum meal
Participants ate more during GHRP-2 exposure than during saline exposure. This is an acute physiology result, not a long-term weight or body-composition study.
Healthy-men endocrine spillover study
- Purpose
- AVP, GH, ACTH, PRL, blood pressure, and fasting effects
- Context
- Human physiology study
- Route
- IV
- Amount
- 100 mcg
- Frequency
- Single bolus with and without fasting
- Duration
- Short provocative-test sampling period
AVP was not stimulated, but GH, ACTH, and prolactin peaks were significant and higher with fasting.
Child PK/PD study
- Purpose
- Pharmacokinetics, pharmacodynamics, and GH kinetics
- Context
- Pediatric human PK/PD study
- Route
- IV
- Amount
- 1 mcg/kg over 1 minute
- Frequency
- Single dose
- Duration
- Short PK/PD sampling period
The study reported predictable biexponential pharmacokinetics and a strong GH rise in prepubertal children.
Six-child exploratory treatment study
- Purpose
- Overnight GH secretion and growth velocity in children with GHD and growth failure
- Context
- Small pediatric exploratory study
- Route
- Subcutaneous
- Amount
- 0.3, 1.0, and 3.0 mcg/kg/day in sequence; then 3 mcg/kg GHRP-2 plus 3 mcg/kg GHRH
- Frequency
- Daily study exposure
- Duration
- Successive 2-month blocks, then combination treatment
The small study reported dose-wise overnight GH increases and higher growth velocity, but IGF-I and IGFBP-3 did not increase and the sample was too small for broad pediatric claims.
Older-adult continuous-infusion physiology
- Purpose
- GH pulsatility and IGF-related biomarkers
- Context
- Human physiology studies
- Route
- Subcutaneous infusion
- Amount
- 1 mcg/kg/hour in the 30-day study
- Frequency
- Continuous infusion
- Duration
- 24-hour protocols and 30 days, depending on study
GH secretion and IGF-related biomarkers rose, but the studies did not show strength, lean-mass, recovery, or anti-aging benefit.
Critical-illness endocrine studies
- Purpose
- GH, TSH, prolactin, and metabolic endocrine effects in prolonged critical illness
- Context
- Human critical-illness studies
- Route
- Infusion
- Amount
- 1 mcg/kg/hour in several arms; some studies combined GHRP-2 with TRH or GnRH
- Frequency
- Continuous or protocolized infusion during the study
- Duration
- 21 hours or 5 days, depending on study
These disease-state studies inform endocrine physiology, not claims about healthy people using secretagogues for performance or body composition.
Real-world discussion
Community secretagogue protocols
- Purpose
- GH release for recovery, appetite, and body composition
- Context
- Forums, vendor listings, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Community protocols usually describe 100 to 300 mcg per injection, two to three times daily, usually fasted.
- Frequency
- Two to three times daily in most descriptions
- Duration
- Typically 8 to 12 week cycles
GHRP-2 is generally described in community sources as stronger on GH release than ipamorelin with less hunger stimulation than GHRP-6, and comparative work found it raises ACTH and cortisol where ipamorelin did not. Human outcome data for marketed uses are absent. Reported as context, not a recommendation.
What varies
- Goal: diagnostic testing, appetite research, pediatric growth research, critical-illness endocrinology, and clinic body-composition programs are different questions.
- Route: labeled IV testing, subcutaneous infusion studies, intranasal programs, and gray-market injectable vials carry their own source and product-quality issues.
- Amount and timing: single diagnostic boluses, continuous infusions, daily pediatric schedules, and repeated clinic-style use have different risk and evidence profiles.
- Blend status: online discussion often mixes GHRP-2 with CJC-1295, ipamorelin, or other secretagogues, which makes attribution difficult.
- Product controls: identity, sterility, endotoxin, concentration, aggregation, impurities, storage, and reconstitution have to be documented beyond a simple purity claim.
Human data
Human evidence
The human evidence is strongest exactly where the market is quietest: diagnostic testing and acute physiology. The Japanese label and validation studies support GHRP-2 as a GH stimulation test, and controlled work documents a real acute appetite increase, about 36% more intake in a small crossover trial, plus ACTH and prolactin spillover. Biomarker studies in older adults and a tiny pediatric treatment exploration show the axis responding without demonstrating functional benefit. The anorexia case report and critical-illness studies are context, not support for healthy-adult use. For muscle gain, fat loss, recovery, sleep, and anti-aging outcomes, the cited record contains no controlled healthy-adult result.
Evidence maturity
GHRP-2 is one of the few community peptides with an actual approval somewhere: as a diagnostic, not for what it is sold for online.
GH-release and GHRH-synergy studies in humans.
Pralmorelin (GHRP-2) approved as a growth-hormone diagnostic in Japan.
None for muscle, recovery, or anti-aging.
Gray-market vials; WADA-prohibited.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Japan pralmorelin product label | Adults and children age 4 to under 18 undergoing GH secretion deficiency testing | Approved diagnostic product information | Approved Japanese diagnostic product | The label describes pralmorelin injection for diagnosing GH secretion deficiency, with fasting IV administration and specified GH sampling. | The label supports diagnostic testing, not repeated use for physique, recovery, sleep, anti-aging, or general wellness. | strong |
| Adult GHRP-2 diagnostic validation | Healthy adults and adults previously classified by insulin tolerance testing as severe GHD | Primary human diagnostic validation study | Diagnostic investigational / clinical testing context | A 100 mcg IV dose after overnight fast produced GH peaks within 60 minutes, and a peak GH cutoff around 15 mcg/L aligned with severe GHD classification. | Diagnostic accuracy is separate from treatment benefit or long-term safety for non-diagnostic use. | strong |
| GHRP-2 compared with ITT and arginine | Japanese adults with pituitary tumors | Comparative diagnostic study | Diagnostic testing context | GHRP-2 produced higher absolute GH peaks overall than ITT and had strong diagnostic performance for severe adult GHD against ITT classification. | This is a specialist diagnostic comparison, not a general benefit study. | moderate |
| Healthy-men appetite and GH study | Seven healthy lean men | Randomized crossover human physiology study | Research infusion | A 1 mcg/kg/hour subcutaneous infusion for 270 minutes increased food intake by 35.9% versus saline and sharply raised GH exposure. | Acute appetite and hormone changes are separate from long-term body composition, strength, or health outcomes. | moderate |
| Healthy-men AVP and endocrine spillover study | Ten healthy men | Human provocative physiology study | Research IV bolus | AVP was not stimulated, but GH, ACTH, and prolactin rose significantly, with higher peaks after fasting. | The study clarifies endocrine effects; it does not test benefit. | moderate |
| GHRH receptor mutation study | People with homozygous GHRH receptor mutation and controls | Human mechanistic study | Research exposure | GHRP-2 still increased GH in mutation carriers, although less than in controls, supporting partial GHRH-independent action. | Mechanism is only a starting point for broad benefit statements. | moderate |
| Pediatric PK/PD study | Ten prepubertal short children | Phase I pharmacokinetic and pharmacodynamic study | Research IV exposure | A single 1 mcg/kg IV dose produced predictable pharmacokinetics and a strong GH rise. | PK/PD data are not growth, safety, or benefit data for broader pediatric use. | moderate |
| Six-child exploratory GHD treatment study | Six prepubertal children with GHD and growth failure | Small exploratory treatment study | Research subcutaneous exposure | Sequential daily dosing increased overnight GH secretion and growth velocity, while IGF-I and IGFBP-3 did not increase. | The sample was tiny, dosing was sequential, and later intranasal work reported no growth promotion. | weak |
| Older-adult physiology studies | Older adults with reduced GH secretion or low IGF-1 | Human physiology studies | Research infusion | Twenty-four-hour and 30-day protocols increased GH secretion and IGF-related biomarkers. | The studies were small biomarker studies, not strength, lean-mass, recovery, or anti-aging outcome trials. | weak |
| Prolonged critical-illness endocrine studies | Critically ill adults | Disease-state endocrine studies | Research infusion, sometimes in combination with TRH or GnRH | Studies reported GH, TSH, prolactin, and metabolic endocrine effects in a highly specific illness setting. | Critical-illness endocrine rescue physiology is a poor shortcut for healthy-adult performance or body-composition claims. | weak |
| Severe anorexia nervosa case report | One severely emaciated patient | Case report | Intranasal case-report use | The case report described improved body weight and hypoglycemia over one year. | A single case gives a concrete clinical story, not a general appetite, weight, or recovery rule. | anecdotal |
Cautions
Safety and unknowns
- The Japanese label lists hot sensation, hypotension, nausea, gastric discomfort, abdominal bloating, somnolence, dizziness, sweating, hunger, headache, facial flushing, and ALT elevation among adverse reactions or safety observations.
- The label contraindicates use in pregnancy and flags lactation context from rat milk-transfer findings. It also states that efficacy and safety trials were not conducted in low-birthweight infants, neonates, infants, or children younger than 4 years.
- GHRP-2 is not GH-only in human physiology studies. ACTH and prolactin responses matter because repeated off-label exposure could affect more than one endocrine axis.
- Longer-term safety outside diagnostic or small physiology studies remains unsettled, including glucose handling, adrenal-axis effects, cardiovascular risk, cancer-related concerns, and immunogenicity.
- Combining GHRP-2 with other diagnostic peptides or GH-axis compounds adds uncertainty. The Japanese label notes that safety with simultaneous administration of other diagnostic peptides such as CRH, GnRH, or TRH had not been studied together in a way the label could rely on.
- Gray-market and compounded products add risks unrelated to the intended molecule: wrong identity, wrong concentration, sterility failure, endotoxin, aggregation, degradation, peptide-related impurities, storage problems, reconstitution errors, and blend confusion.
Product quality
A vial label is only a starting point
GHRP-2 is an injectable peptide in most clinic and gray-market discussion, so product quality is not a side issue. Sterility, endotoxin control, impurity profile, concentration, aggregation, storage, and chain of custody all matter.
FDA compounding materials specifically flag GHRP-2 for potential immunogenicity related to aggregation and peptide-related impurities, and note characterization complexity. A visible purity percentage or seller COA does not answer the full quality question.
Forum discussion about cloudy solutions, blends, and handling uncertainty is not efficacy evidence, but it is a reminder that marketed peptide products can create practical risks even before any claimed benefit is considered.
Identity
A vial label or blend name still leaves identity, intended salt or form, and match to studied material open.
Sterility and endotoxin
Injectable-use risk depends on microbial and endotoxin controls, not just peptide purity.
Impurities and aggregation
FDA's GHRP-2 concern includes peptide-related impurities and aggregation, both of which can affect immunogenicity risk.
Concentration and dose math
Lyophilized vial amount, diluent volume, final concentration, and syringe units all have to align. A concentration mistake changes exposure even if the peptide identity is correct.
Storage and handling
Temperature, light exposure, reconstitution, shipping, and repeated vial punctures can affect stability and contamination risk.
Mechanism
How it is proposed to work
GHRP-2 acts through a ghrelin-like pathway at the growth hormone secretagogue receptor. In plain terms, it can tell the body to release more growth hormone for a short period, while also interacting with appetite and other pituitary hormone effects.
The Japanese label describes receptor binding that promotes GH secretion, mainly through hypothalamic mediation. Human studies confirm that the GH response is real.
GHRP-2 is not just GHRH under another name. A human mutation study found GH response even with impaired GHRH receptor signaling, and combination work suggests partially independent but synergistic pathways.
The ghrelin-like action helps explain appetite findings. In controlled humans, GHRP-2 increased food intake, which makes simple fat-loss marketing especially weak.
ACTH, prolactin, and broader pituitary effects show that the molecule is not limited to GH alone.
GHRP-2 (D-Ala-D-2Nal hexapeptide) is a ghrelin-receptor agonist and, as pralmorelin, an approved GH diagnostic in Japan. Comparative endocrine work shows it raises ACTH and cortisol alongside GH: the non-selectivity that separates it from ipamorelin.
FAQ
Common questions
Is GHRP-2 the same as pralmorelin?
Yes. Pralmorelin is the drug name for GHRP-2, which is approved in Japan as a diagnostic agent for growth-hormone secretion. That approval covers diagnostic testing, not the physique and anti-aging claims made online.
What does community use look like?
Community protocols commonly describe 100 to 300 mcg per injection, two to three times daily, usually fasted, in 8 to 12 week cycles.
How does GHRP-2 compare to ipamorelin?
GHRP-2 is generally the stronger secretagogue per microgram but less selective — comparative work found it raises ACTH and cortisol where ipamorelin did not. See the ipamorelin vs GHRP-2 comparison page for the full contrast.
Details
Technical details
Sources
References
- 1.
Japan pralmorelin label. KEGG/JAPIC listing for GHRP Kaken 100, including 2022 package insert details.
Official product information - Japan indication, dose, adverse effects, PK, chemistry
- 2.
Chihara diagnostic study. Chihara et al., *European Journal of Endocrinology* 2007, adult GHRP-2 diagnostic validation.
Primary human clinical study - Diagnostic sensitivity, reproducibility, cutoff
- 3.
Kinoshita comparison. Kinoshita et al., *Endocrine Journal* 2013, GHRP-2 versus ITT and arginine in Japanese adults.
Primary human clinical study - Comparative diagnostic accuracy
- 4.
Laferrere appetite study. Laferrère et al., *JCEM* 2005, healthy-men appetite and GH study.
Primary human clinical study - Acute food intake and GH response
- 5.
Laferrere obese-subject appetite study. Laferrère et al., obese-subject appetite-response PubMed abstract.
Primary human abstract record - Appetite response in obesity
- 6.
GHRH mutation study. Gondo et al., *JCEM* 2001, GH response in GHRH receptor mutation.
Primary mechanistic human study - Partial GHRH-independent action
- 7.
Kamoi AVP study. Kamoi et al., *Endocrine Journal* 2010, healthy men, AVP not stimulated, GH/ACTH/PRL higher with fasting.
Primary human physiology study - Spillover and fasting effect
- 8.
Kimura ACTH study. Kimura et al., *Endocrine Journal* 2010, hypothalamic-pituitary disorders and ACTH release.
Primary human clinical study - ACTH mechanism
- 9.
Pihoker child PK/PD. Pihoker et al., *JCEM* 1998, child PK/PD study.
Primary human clinical study - PK and PD details
- 10.
Mericq pediatric study. Mericq et al., *JCEM* 1998, 8-month GHD children study.
Primary human clinical study - Small pediatric treatment signal
- 11.
Intranasal pediatric paper. Tanaka et al., 2014 intranasal GHRP-2 pediatric paper titled “Does Not Promote Growth.”
Primary human abstract record - Pediatric intranasal counter-signal
- 12.
Bowers older-adult studies. Bowers et al., older-adult GHRP-2 physiology studies, 2001 and 2004.
Primary human physiology studies - 24-h and 30-d GH and IGF biomarker data
- 13.
Critical-illness studies. Van den Berghe et al., prolonged critical illness studies, 1999 to 2002.
Primary human clinical studies - Disease-state endocrine and metabolic effects
- 14.
Anorexia case report. Haruta et al., 2015 anorexia nervosa case report.
Primary case report record - Very low-certainty appetite and weight signal
- 15.
FDA orphan record. FDA orphan designation record for pralmorelin hydrochloride with status “Not FDA Approved for Orphan Indication.”
Official U.S. regulatory record - U.S. approval status
- 16.
FDA compounding context. FDA category 2 compounding page and warning letters mentioning GHRP-2.
Official U.S. regulatory records - Compounding and unapproved-drug context
- 17.
FDA peptide quality. FDA peptide impurity and characterization materials.
Official scientific and regulatory materials - COA and impurity-risk framing
- 18.
Supplement adulteration. Thomas et al., identification of GHRP-2 in a nutritional supplement.
Primary analytical case report - Adulteration and gray-market risk
- 19.
Vendor examples. Current vendor pages advertising purity and COA claims.
Gray-market example - purity and COA language in online listings
- 20.
Clinic examples. Clinic pages making recovery and fat-loss style claims.
Clinic-market example - recovery and fat-loss claims in clinic marketing
- 21.
Forum reports. Reddit pages discussing clouds, blends, and stacks.
Anecdotal example - handling and formulation uncertainty
- 22.
FTC health-claim guidance. FTC Health Products Compliance Guidance.
Official marketing standard - Advertising substantiation context